Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation.


Serval ID
Article: article from journal or magazin.
Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation.
American Heart Journal
Camenzind E., Wijns W., Mauri L., Boersma E., Parikh K., Kurowski V., Gao R., Bode C., Greenwood J.P., Gershlick A., O'Neill W., Serruys P.W., Jorissen B., Steg P.G.
Working group(s)
PROTECT Steering Committee, Investigators
Camenzind E., Mauri L., O'Neill W., Serruys PW., Steg PG., Wijns W., Verheugt FW., Bertrand ME., Califf R., DeMets D., Wallentin L., Bosmans J., Hanet C., Herrman JP., Kelbaek H., Mc Fadden E., Radke PW., RutschC W., Tilsted HH., Boersma E., Alvarez C., Rodriguez A., Meredith I., Muller D., Whitbourn R., Worthley S., Whelan A., Walters D., Shetty S., New G., Cox S., Batra R., van Gaal W., Bellamy G., Mayr H., Heigert M., Huber K., Leisch F., Wijns W., Desmet W., Boland J., Chenu P., Legrand V., Labinaz M., Teefy P., Bertrand O., Gao R., Ge J., Kala P., Cervinka P., Urena P., Hartikainen J., Steg G., Fajadet J., Carrié D., Gilard M., Barragan P., Lablanche JM., Koning R., Eltchaninoff H., Darremont O., Leroy F., Bertrand B., Robert G., Schiele F., Chassaing S., Brunel P., Quilliet L., Brunet J., Pansieri M., Stratiev V., Teiger E., Lebreton H., Bonnet JL., Karsenty B., Delarche N., Cassagnes J., Brachmann J., Kurowski V., Buerke M., Schieffer B., Wiemer M., Schächinger V., Boekstegers P., Genth-Zotz S., Bode C., Frey N., Neumann FJ., Pels K., Strasser R., Kuck KH., Hauptmann KE., Heitzer T., Haude M., Hoffmann E., Jung W., Hoffmann S., Schmitt C., Dissmann M., Pauschinger M., Werner G., Braun-Delleus R., Manz M., Voudris V., Sionis D., Kang-Yin M., Tse TS., Merkely B., Mehta A., Parikh K., Chandra P., Rath P., Hiremath S., Manoharan G., Crean P., Daly K., Kornowski R., Kerner A., Mosseri M., Jafari G., Giudice P., Trani C., Manari A., Prati F., Pangrazi A., Bolognese L., Jeong MH., Kim MH., Kim H., Park SJ., Erglis A., Kalnins A., Wagner D., Zambahari R., Sim K., den Heijer P., Appelman Y., Suttorp MJ., de Smet B., Koolen J., Stella P., Harding S., Maslowski A., Abernethy M., Devlin G., Rotevatn S., Myreng Y., Ciecwierz D., Peruga J., Reczuch K., Campante Teles R., Abreu PF., Leitão-Marques A., Pereira H., Vinereanu D., Alkasab S., Al Kurdi M., Al Turki F., Wong P., Teo S., Ruigomez FJ., Chávarri MV., Gonzalez AB., Romo AI., Minguez£££J López£££ JL. , García£££J-M Hernández£££ JM. , Fernández JD., Salmeron RR., Elbal LM., Zueco J., Lopez-Palop R., Melgares R., Herterich O., Olivencrona G., Fröbert O., Roffi M., Girod G., Vuilliomenet A., Hsieh IC., Wu CJ., Gershlick A., Densem C., Doshi S., McCarthy P., De Belder M., Mills J., Fath-Ordoubadi F., Simpson I., Greenwood J., Khan Z., Cotton J., Gunning M., Smith D., Talwar S., Holmberg S., Purcell I., Anderson R., Alamgir F., Beatt K., Kelly P., Moussavian M., Aji J., Prashad R., Banerjee S., Lewis S., McLauren B., Douglas J., Brenner S., Gupta A., Walters L., Driesman M., Aycock R., Mego C., Fisher D., Frankel R., Satler L.
1097-6744 (Electronic)
Publication state
Issued date
Publication types: Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Drug-eluting stents (DES) reduce restenosis rates compared to bare-metal stents. Most trials using DES enrolled selected patient and lesion subtypes, and primary endpoint focused on angiographic metrics or relatively short-term outcomes. When DES are used in broader types of lesions and patients, important differences may emerge in long-term outcomes between stent types, particularly the incidence of late stent thrombosis. PROTECT is a randomized, open-label trial comparing the long-term safety of the zotarolimus-eluting stent and the sirolimus-eluting stent. The trial has enrolled 8,800 patients representative of those seen in routine clinical practice, undergoing elective, unplanned, or emergency procedures in native coronary arteries in 196 centers in 36 countries. Indications for the procedure and selection of target vessel and lesion characteristics were at the operator's discretion. Procedures could be staged, but no more than 4 target lesions could be treated per patient. Duration of dual antiplatelet therapy was prespecified to achieve similar lengths of treatment in both study arms. The shortest predefined duration was 3 months, as per the manufacturer's instructions. The primary outcome measure is the composite rate of definite and probable stent thrombosis at 3 years, centrally adjudicated using Academic Research Consortium definitions. The main secondary end points are 3-year all-cause mortality, cardiac death, large nonfatal myocardial infarction, and all myocardial infarctions. This large, international, randomized, controlled trial will provide important information on comparative rates of stent thrombosis between 2 different DES systems and safety as assessed by patient-relevant long-term clinical outcomes.
Drug-Eluting Stents/adverse effects, Humans, Incidence, Prosthesis Design, Research Design, Sirolimus/administration & dosage, Sirolimus/analogs & derivatives, Thrombosis/epidemiology, Thrombosis/etiology
Web of science
Create date
20/01/2010 16:27
Last modification date
20/08/2019 17:22
Usage data